Type-1, -2, and -3 inflammation and severity of decompensated cirrhosis

Type-1, Type-2, and Type-3 inflammation are classifications of immune responses that represent distinct biological pathways activated in response to different types of stimuli. These inflammation types play critical roles in the progression and severity of acutely decompensated cirrhosis (ADC) and acute-on-chronic liver failure (ACLF). Below is a detailed explanation of these inflammation types, their roles in cirrhosis, and how they influence disease severity:

---

### **Type-1 Inflammation**

**Definition:**

Type-1 inflammation is primarily associated with antiviral and antibacterial defense mechanisms. It involves immune responses aimed at clearing intracellular pathogens, such as viruses and certain bacteria.

**Key Markers:**

• **IFN-γ (Interferon-gamma):** A cytokine critical for antiviral defense and intracellular bacterial clearance.
• **IL-1β (Interleukin-1 beta):** A pro-inflammatory cytokine involved in acute immune activation.
• **IgG (Immunoglobulin G):** An antibody that supports pathogen neutralization.

**Role in ADC and ACLF:**

• **Suppression:** In patients with ADC, type-1 inflammation is suppressed as disease severity progresses. IFN-γ levels decrease significantly, impairing the ability to fight viral infections (e.g., hepatitis B virus [HBV] flares) and intracellular bacterial infections.
• **Immune Dysregulation:** Reduced IFN-γ and depletion of T-cells (especially CD3+ and CD4+ T-cells) lead to immune exhaustion and increased susceptibility to secondary infections, which are common in ACLF patients.
• **Impact on Prognosis:** The suppression of type-1 inflammation contributes to poor antiviral control and worsens outcomes, including increased mortality risk.

---

### **Type-2 Inflammation**

**Definition:**

Type-2 inflammation is primarily involved in tissue repair and defense against extracellular parasites (e.g., helminths). It plays a role in maintaining epithelial barrier integrity and promoting wound healing.

**Key Markers:**

• **IL-25 (Interleukin-25):** An initiating cytokine that activates type-2 responses.
• **IL-13 (Interleukin-13):** An effector cytokine that supports tissue repair.
• **IL-4 (Interleukin-4):** A cytokine involved in regulating immune responses and promoting anti-inflammatory effects.

**Role in ADC and ACLF:**

• **Dysregulation:** In ADC patients, type-2 inflammation becomes dysregulated. IL-25 levels steadily rise, but IL-13 levels decline at the ACLF stage, indicating incomplete or defective tissue repair mechanisms.
• **Barrier Dysfunction:** The paradoxical rise in IL-25 alongside reduced IL-13 suggests impaired epithelial barrier integrity, contributing to “leaky gut” syndrome. This allows bacterial translocation and systemic inflammation, exacerbating liver damage.
• **Progression:** Dysregulated type-2 responses are linked to tissue repair failure, further driving disease progression toward ACLF.

---

### **Type-3 Inflammation**

**Definition:**

Type-3 inflammation is associated with responses to extracellular pathogens, such as bacteria and fungi, and is characterized by sustained pro-inflammatory activation.

**Key Markers:**

• **IL-6 (Interleukin-6):** A central cytokine driving systemic inflammation.
• **IL-23 (Interleukin-23):** A cytokine involved in promoting chronic inflammation.
• **IL-22 (Interleukin-22):** A cytokine that supports epithelial defense but also contributes to inflammation.
• **MIP-3α (Macrophage Inflammatory Protein-3 alpha):** A chemokine involved in recruiting immune cells to sites of infection.

**Role in ADC and ACLF:**

• **Hyperactivation:** Type-3 inflammation becomes progressively hyperactivated as ADC severity increases. Levels of IL-6, IL-23, and IL-22 rise sharply and peak in ACLF patients.
• **Systemic Inflammation:** Excessive type-3 activation drives systemic immune activation, leading to further organ damage and worsening liver function.
• **Mortality Risk:** Elevated IL-6 and IL-22 levels strongly correlate with short-term mortality (28-day mortality), highlighting their role in predicting poor outcomes.

---

### **Acutely Severe Decompensated Cirrhosis (ADC)**

**Definition:**

Acutely decompensated cirrhosis refers to the sudden worsening of liver function in patients with chronic liver disease. This condition is characterized by complications such as jaundice, ascites (fluid accumulation in the abdomen), hepatic encephalopathy (brain dysfunction due to liver failure), and gastrointestinal bleeding.

**Stages of ADC Severity:**

1. **No Organ Dysfunction (No-OD):** Mild stage with preserved organ function.

2. **Organ Dysfunction (OD):** Intermediate stage with partial impairment of organ function.

3. **Organ Failure (OF) Without ACLF:** Severe stage with significant organ failure but not meeting ACLF criteria.

4. **ACLF (Acute-on-Chronic Liver Failure):** The most severe stage, characterized by multi-organ failure, systemic inflammation, and high short-term mortality.

**Systemic Inflammation in ADC:**

• Systemic inflammation is a hallmark of ADC and drives its progression toward ACLF.
• Immune dysregulation, characterized by neutrophilia (high neutrophil count), lymphopenia (low lymphocyte count), and altered cytokine levels, contributes to worsening liver function and organ failure.
• Inflammation occurs independently of clinical precipitants like infections or alcohol-related injury, indicating intrinsic immune abnormalities.

---

### **How Type-1, Type-2, and Type-3 Inflammation Work in Cirrhosis**

1. **Type-1 Suppression:**

• Reduced IFN-γ and T-cell depletion impair the clearance of intracellular pathogens (e.g., HBV), increasing susceptibility to secondary infections.
• This contributes to immune exhaustion and progression toward ACLF.

2. **Type-2 Dysregulation:**

• Elevated IL-25 and reduced IL-13 reflect defective tissue repair signaling, leading to epithelial barrier dysfunction (e.g., “leaky gut”).
• Bacterial translocation and systemic inflammation exacerbate liver damage and promote disease progression.

3. **Type-3 Hyperactivation:**

• Excess IL-6, IL-23, and IL-22 drive chronic systemic inflammation, leading to further organ damage.
• These cytokines correlate strongly with disease severity and short-term mortality, making them critical markers for predicting outcomes.

---

### **Key Findings and Implications**

• **Independent Predictors of Progression:** Neutrophilia, lymphopenia, decreased IFN-γ, elevated IL-25, IL-6, IL-22, and sCD163 were identified as independent predictors of progression from organ dysfunction (OD) to ACLF.
• **Risk of Organ Failure:** Elevated white blood cell and neutrophil counts, alongside higher levels of IL-25, IL-23, and IL-22, were strongly associated with transition to organ failure and ACLF.
• **28-Day Mortality:** Cytokines like IL-6, IL-22, MIP-3α, and sCD163 were elevated in patients who died within 28 days, while lymphocyte and T-cell counts were lower, highlighting their predictive power for short-term mortality.

---

### **Conclusion**

The severity of acutely decompensated cirrhosis is characterized by a triad of immune responses: type-1 suppression, type-2 dysregulation, and type-3 hyperactivation. These inflammatory signatures are independent of precipitating events (e.g., infection, alcohol injury) and serve as potential biomarkers for early prediction of ACLF risk. Understanding these mechanisms can guide the development of immunomodulatory therapies aimed at improving outcomes in ADC and ACLF patients.